Piper Sandler Downgrades IO Biotech Amid Strategic Uncertainty
Piper Sandler lowers IO Biotech to Neutral, citing strategic plans and capital limits, with a new price target of $0.50.
/ 904 items
#Healthcare↓
Israeli Medical Aesthetics Firm InMode Set for $1.1B Acquisition Deal
InMode, the Israeli medical aesthetics technology company, is in advanced talks for a $1.1 billion acquisition by a foreign investment fund, representing a 25% premium.
Sarepta's Elevidys Gene Therapy Shows Lasting Benefits Three Years After Treatment for Duchenne Muscular Dystrophy
Sarepta Therapeutics reports positive three-year results for Elevidys gene therapy in Duchenne patients, showing 70% slowing of disease progression and sustained motor function improvements, boosting investor confidence.
Oppenheimer Turns Bullish on Relay Therapeutics Ahead of Key Data
Oppenheimer upgrades Relay Therapeutics to Outperform, citing potential upside from competitor trial risks and upcoming VIKTORIA-1 results.
FDA Approves New Dosing Guidelines for Afrezza Inhaled Insulin
MannKind (MNKD) receives FDA approval for updated Afrezza dosing recommendations, making it easier for patients to switch from insulin injections to inhaled insulin therapy.
Merck Ends Talks to Buy Cancer Biotech Revolution Medicines in $30B Deal
Merck has walked away from negotiations to acquire Revolution Medicines after failing to agree on price for the promising cancer drug developer valued around $30 billion.